Welcome to our dedicated page for Lixte Biotechnology Hldgs news (Ticker: LIXT), a resource for investors and traders seeking the latest updates and insights on Lixte Biotechnology Hldgs stock.
Lixte Biotechnology Holdings, Inc. reports clinical-stage oncology developments centered on LB-100, its proprietary first-in-class PP2A inhibitor. Recurring updates describe proof-of-concept work in ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma, including combination studies with immunotherapy and other cancer-treatment approaches.
The company also issues news on its broader cancer-treatment platform, including Liora Technologies Europe, radiotherapy technology, patent coverage, trial-site and collaborator activity, capital raises, annual-report highlights, executive and board changes, and investor-conference participation. Its public updates frame LIXT as a clinical-stage pharmaceutical and med-tech issuer focused on new targets for cancer drug development.
LIXTE (Nasdaq: LIXT) announced an expansion of its ongoing ovarian clear cell cancer trial combining its compound LB-100 with GSK's dostarlimab. The study, initiated in January 2024, will double enrollment from 21 to 42 patients across two sites: MD Anderson and the Robert H. Lurie Comprehensive Cancer Center at Northwestern. The trial is led by Amir Jazaeri, MD, and Emily M. Hinchcliff, MD, MPH. LIXTE expects initial data from the first 21 patients to be presented in the first half of 2026. The company framed the expansion as progress toward evaluating LB-100’s potential to enhance immunotherapy and chemotherapy outcomes.
Lixte Biotechnology (NASDAQ: LIXT) entered definitive agreements for a registered direct offering to raise approximately $4.3 million by selling 1,051,342 Common Units (or Pre-Funded Units) at a public offering price of $4.09 per Common Unit (or $4.08999 per Pre-Funded Unit). Each unit includes one share or one pre-funded warrant plus one common warrant exercisable at $3.96 and expiring 60 months after issuance. Pre-Funded Warrants are immediately exercisable. The offering is priced at the market under Nasdaq rules and is expected to close on or about December 19, 2025. Proceeds are intended for general corporate purposes and working capital.
Spartan Capital Securities is exclusive placement agent; offering made from an effective Form S-3 shelf (declared effective May 2, 2024).
LIXTE (NASDAQ:LIXT) is advancing its lead clinical-stage PP2A inhibitor LB-100 and shifting toward a multi-modal oncology platform as of December 3, 2025. Key developments include active collaborations testing LB-100 with dostarlimab (GSK) and atezolizumab (Roche), a temporary safety pause in the metastatic microsatellite-stable colon-cancer combo trial, and prior Phase 1 tolerability data in soft-tissue sarcoma. Strategically, LIXTE announced the acquisition of Liora Technologies Europe Ltd. (LiGHT proton therapy system) and reported converting about $2.6 million of treasury into digital/convertible assets, part of talks to acquire complementary oncology assets to broaden its pipeline.
Those moves expand LIXTE from a single‑asset biotech toward a diversified science and infrastructure strategy combining drugs, radiation hardware, and balance-sheet flexibility.
LIXTE Biotechnology (NASDAQ:LIXT) on December 3, 2025 outlined progress for its PP2A inhibitor LB-100, positioning the drug as an "amplifier" to boost chemo, radiation, and immunotherapy.
Key points: Phase 1 tolerability reported with no toxicity concerns; partnerships with GSK (dostarlimab, full funding for ovarian program) and Roche (atezolizumab, full funding for colorectal study); enrollment finished in a Phase 1b soft-tissue sarcoma trial but further development there is paused to focus on combinations. Company also restored Nasdaq compliance and added digital assets to its treasury.
LIXTE Biotechnology (Nasdaq: LIXT) completed the acquisition of UK-based Liora Technologies Europe Ltd. on November 25, 2025, making Liora a wholly owned subsidiary and adding the proprietary LiGHT System (Linac for Image Guided Hadron Therapy) to LIXTE’s assets.
The LiGHT System is installed at STFC’s Daresbury Laboratory, where STFC will provide resources to develop a center of excellence. The release notes $300+ million invested to date in developing the technology and describes LIXTE’s plan to pursue a recurring revenue model through jointly operated treatment centers while complementing ongoing LB-100 clinical trials.
LIXTE Biotechnology Holdings (Nasdaq: LIXT) announced that CEO Geordan Pursglove will present at the Spartan Capital Investor Conference 2025 in New York on November 3, 2025 at 4:00 PM ET. Management will also hold one-on-one investor meetings during the conference.
The event is at the Marriott Marquis, 1535 Broadway. Investors can register or schedule meetings via the conference website at https://spartancapital.com/spartan-capital-investor-conference-2025/.
LIXTE Biotechnology Holdings (Nasdaq: LIXT) on Oct 16, 2025 outlined Q4 priorities centered on advancing its lead candidate LB-100 and pursuing oncology-focused business development. The company said it is continuing clinical and preclinical work on LB-100 across prioritized tumor settings and maintaining collaborations with research centers.
LIXTE confirmed it is in advanced negotiations for potential acquisitions of complementary oncology assets to build a multi-asset platform, while noting no assurance any transaction will close. Operational readiness initiatives in quality, CMC, and regulatory alignment were highlighted to support study conduct and potential integration.
LIXTE Biotechnology Holdings (Nasdaq: LIXT), a clinical stage pharmaceutical company, has invested $2.6 million in cryptocurrencies, purchasing 10.5 Bitcoin (BTC) and 300 Ethereum (ETH). This strategic move represents approximately 43.6% of LIXTE's treasury holdings.
The company's Board of Directors has approved an increased allocation of up to 50% of its treasury to cryptocurrencies. The investment aims to diversify treasury holdings and enhance the company's ability to conduct transactions across multiple mediums of exchange, positioning LIXTE for greater adaptability in the digital economy.
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company developing cancer therapies, has announced significant leadership changes and a corporate relocation. The company has appointed Lourdes Felix and Guy Primus to its Board of Directors and named Peter Stazzone as Chief Financial Officer.
The company has relocated its corporate headquarters to Boca Raton, Florida, citing a business-friendly environment and cost reduction benefits. These changes follow the appointment of Geordan Pursglove as Chairman and CEO in June 2025. Former board members Bas van der Baan will continue as Chief Scientific Officer, while René Bernards has been appointed Chairman of LIXTE's Scientific Advisory Board.
The new appointments bring significant expertise to LIXTE: Stazzone contributes over 20 years of financial management experience, Felix brings 30+ years in management and finance, and Primus adds 30 years of technology and innovation leadership experience.
LIXTE Biotechnology (NASDAQ:LIXT) announced significant corporate developments, including successful completion of two financings totaling $6.5 million and regaining Nasdaq compliance. The company appointed Geordan Pursglove as Chairman and CEO, while former CEO Bas van der Baan transitioned to President and CSO.
The company's proprietary compound LB-100 received validation through findings published in Nature, demonstrating improved survival outcomes in cancer patients with specific mutations. Clinical trials for ovarian and colorectal cancer are ongoing at prestigious institutions including MD Anderson Cancer Center and Northwestern University, with support from GSK and Roche. Additionally, LIXTE launched a new pre-clinical study with the Netherlands Cancer Institute exploring cancer prevention possibilities.